References
- Thuret I. Post-transfusional iron overload in the haemoglobinopathies. C R Biol. 2013 Mar;336(3):164–172. doi:10.1016/j.crvi.2012.09.010. PubMed PMID: 23643400.
- Origa R, Galanello R, Ganz T, et al. Liver iron concentrations and urinary hepcidin in beta-thalassemia. Haematologica. 2007 May;92(5):583–588. PubMed PMID: 17488680. doi: https://doi.org/10.3324/haematol.10842
- Porter J, Garbowski M. Consequences and management of iron overload in sickle cell disease. Hematology Am Soc Hematol Educ Program. 2013;2013:447–456. doi:10.1182/asheducation-2013.1.447. PubMed PMID: 24319218.
- Wood JC. Impact of iron assessment by MRI. Hematology Am Soc Hematol Educ Program. 2011;2011:443–450. doi:10.1182/asheducation-2011.1.443. PubMed PMID: 22160072.
- Cappellini MD, Porter J, El-Beshlawy A, et al. Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias. Haematologica. 2010 Apr;95(4):557–566. doi:10.3324/haematol.2009.014696. PubMed PMID: 19951979; PubMed Central PMCID: PMCPMC2857545.
- Lobo C, Angulo IL, Aparicio LR, et al. Retrospective epidemiological study of Latin American patients with transfusional hemosiderosis: the first Latin American epidemiological study in iron overload--the RELATH study. Hematology. 2011 Sep;16(5):265–273. doi:10.1179/102453311X13085644680302. PubMed PMID: 21902889.
- Beard JL, Dawson H, Pinero DJ. Iron metabolism: a comprehensive review. Nutr Rev. 1996 Oct;54(10):295–317. PubMed PMID: 9063021. doi: https://doi.org/10.1111/j.1753-4887.1996.tb03794.x
- Araujo A, Drelichman G, Cancado RD, et al. Management of transfusional iron overload in Latin america: current outlook and expert panel recommendations. Hematology. 2009 Feb;14(1):22–32. doi:10.1179/102453309X385179. PubMed PMID: 19154661.
- Viprakasit V, Gattermann N, Lee JW, et al. Geographical variations in current clinical practice on transfusions and iron chelation therapy across various transfusion-dependent anaemias. Blood Transfus. 2013 Jan;11(1):108–122. doi:10.2450/2012.0012-12. PubMed PMID: 22871821; PubMed Central PMCID: PMC3557481.
- Marsella M, Borgna-Pignatti C. Transfusional iron overload and iron chelation therapy in thalassemia major and sickle cell disease. Hematol Oncol Clin North Am. 2014 Aug;28(4):703–727, vi. doi:10.1016/j.hoc.2014.04.004. PubMed PMID: 25064709.
- Steensma DP, Gattermann N. When is iron overload deleterious, and when and how should iron chelation therapy be administered in myelodysplastic syndromes? Best Pract Res Clin Haematol. 2013 Dec;26(4):431–444. doi:10.1016/j.beha.2013.09.009. PubMed PMID: 24507819.
- Porter JB. Pathophysiology of transfusional iron overload: contrasting patterns in thalassemia major and sickle cell disease. Hemoglobin. 2009;33(Suppl 1):S37–S45. doi:10.3109/03630260903346627. PubMed PMID: 20001631.
- Shander A, Cappellini MD, Goodnough LT. Iron overload and toxicity: the hidden risk of multiple blood transfusions. Vox Sang. 2009 Oct;97(3):185–197. doi:10.1111/j.1423-0410.2009.01207.x. PubMed PMID: 19663936.
- Walters MC. Sickle cell anemia and hematopoietic cell transplantation: when is a pound of cure worth more than an ounce of prevention? Pediatr Transplant. 2004 Jun;8(Suppl 5):33–38. doi:10.1111/j.1398-2265.2004.00188.x. PubMed PMID: 15125704.
- Fillet G, Beguin Y, Baldelli L. Model of reticuloendothelial iron metabolism in humans: abnormal behavior in idiopathic hemochromatosis and in inflammation. Blood. 1989 Aug 1;74(2):844–851. PubMed PMID: 2502204.
- Bourantas KL, Dalekos GN, Makis A, et al. Acute phase proteins and interleukins in steady state sickle cell disease. Eur J Haematol. 1998 Jul;61(1):49–54. PubMed PMID: 9688292. doi: https://doi.org/10.1111/j.1600-0609.1998.tb01060.x